Literature DB >> 16012941

The natural history of nonalcoholic fatty liver disease: a population-based cohort study.

Leon A Adams1, James F Lymp, Jenny St Sauver, Schuyler O Sanderson, Keith D Lindor, Ariel Feldstein, Paul Angulo.   

Abstract

BACKGROUND & AIMS: The natural history of nonalcoholic fatty liver disease (NAFLD) in the community remains unknown. We sought to determine survival and liver-related morbidity among community-based NAFLD patients.
METHODS: Four hundred twenty patients diagnosed with NAFLD in Olmsted County, Minnesota, between 1980 and 2000 were identified using the resources of the Rochester Epidemiology Project. Medical records were reviewed to confirm diagnosis and determine outcomes up to 2003. Overall survival was compared with the general Minnesota population of the same age and sex.
RESULTS: Mean (SD) age at diagnosis was 49 (15) years; 231 (49%) were male. Mean follow-up was 7.6 (4.0) years (range, 0.1-23.5) culminating in 3192 person-years follow-up. Overall, 53 of 420 (12.6%) patients died. Survival was lower than the expected survival for the general population (standardized mortality ratio, 1.34; 95% CI, 1.003-1.76; P = .03). Higher mortality was associated with age (hazard ratio per decade, 2.2; 95% CI, 1.7-2.7), impaired fasting glucose (hazard ratio, 2.6; 95% CI, 1.3-5.2), and cirrhosis (hazard ratio, 3.1, 95% CI, 1.2-7.8). Liver disease was the third leading cause of death (as compared with the thirteenth leading cause of death in the general Minnesota population), occurring in 7 (1.7%) subjects. Twenty-one (5%) patients were diagnosed with cirrhosis, and 13 (3.1%) developed liver-related complications, including 1 requiring transplantation and 2 developing hepatocellular carcinoma.
CONCLUSIONS: Mortality among community-diagnosed NAFLD patients is higher than the general population and is associated with older age, impaired fasting glucose, and cirrhosis. Liver-related death is a leading cause of mortality, although the absolute risk is low.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16012941     DOI: 10.1053/j.gastro.2005.04.014

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  932 in total

1.  Visual Liver Score to Stratify Non-Alcoholic Steatohepatitis Risk and Determine Selective Intraoperative Liver Biopsy in Obesity.

Authors:  Geraldine J Ooi; Paul R Burton; Arul Earnest; Cheryl Laurie; William W Kemp; Peter D Nottle; Catriona A McLean; Stuart K Roberts; Wendy A Brown
Journal:  Obes Surg       Date:  2018-02       Impact factor: 4.129

2.  Digital quantification is more precise than traditional semiquantitation of hepatic steatosis: correlation with fibrosis in 220 treatment-naïve patients with chronic hepatitis C.

Authors:  Sekou R Rawlins; Ola El-Zammar; J Michael Zinkievich; Nancy Newman; Robert A Levine
Journal:  Dig Dis Sci       Date:  2010-05-12       Impact factor: 3.199

3.  NAFLD and insulin resistance do not increase the risk of postoperative complications among patients undergoing bariatric surgery--a prospective analysis.

Authors:  Tarsila Ribeireiro; James Swain; Michael Sarr; Michael Kendrick; Florencia Que; Schuyler Sanderson; Anuradha Krishnan; Kimberly Viker; Kymberly Watt; Michael Charlton
Journal:  Obes Surg       Date:  2011-03       Impact factor: 4.129

Review 4.  Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease.

Authors:  Donald B Jump; Kelli A Lytle; Christopher M Depner; Sasmita Tripathy
Journal:  Pharmacol Ther       Date:  2017-07-16       Impact factor: 12.310

5.  Hepatic glucose uptake is increased in association with elevated serum γ-glutamyl transpeptidase and triglyceride.

Authors:  Sun-pyo Hong; Tae Soo Noh; Seung-Hwan Moon; Young Seok Cho; Eun Jeong Lee; Joon Young Choi; Byung-Tae Kim; Kyung-Han Lee
Journal:  Dig Dis Sci       Date:  2013-12-11       Impact factor: 3.199

6.  Elevated serum uric acid levels are associated with non-alcoholic fatty liver disease independently of metabolic syndrome features in the United States: Liver ultrasound data from the National Health and Nutrition Examination Survey.

Authors:  Jeffrey C Sirota; Kim McFann; Giovanni Targher; Richard J Johnson; Michel Chonchol; Diana I Jalal
Journal:  Metabolism       Date:  2012-10-02       Impact factor: 8.694

7.  Nonalcoholic fatty liver disease (NAFLD): is it really a serious condition?

Authors:  Julia Wattacheril; Naga Chalasani
Journal:  Hepatology       Date:  2012-10       Impact factor: 17.425

8.  Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: potential role in fructose-dependent and -independent fatty liver.

Authors:  Miguel A Lanaspa; Laura G Sanchez-Lozada; Yea-Jin Choi; Christina Cicerchi; Mehmet Kanbay; Carlos A Roncal-Jimenez; Takuji Ishimoto; Nanxing Li; George Marek; Murat Duranay; George Schreiner; Bernardo Rodriguez-Iturbe; Takahiko Nakagawa; Duk-Hee Kang; Yuri Y Sautin; Richard J Johnson
Journal:  J Biol Chem       Date:  2012-10-03       Impact factor: 5.157

Review 9.  Non-alcoholic fatty liver disease: a diabetologist's perspective.

Authors:  Joseph M Pappachan; Farrah A Antonio; Mahamood Edavalath; Arjun Mukherjee
Journal:  Endocrine       Date:  2013-11-28       Impact factor: 3.633

10.  Testosterone replacement ameliorates nonalcoholic fatty liver disease in castrated male rats.

Authors:  L Nikolaenko; Y Jia; C Wang; M Diaz-Arjonilla; J K Yee; S W French; P Y Liu; S Laurel; C Chong; K Lee; Y Lue; W N P Lee; R S Swerdloff
Journal:  Endocrinology       Date:  2013-11-26       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.